tbuckley/cabot-search huggingface dataset:
Renal failure, uncontrollable thirst, and hyperreninemia. Cessation of thirst with bilateral nephrectomy
Authors: P. W. Rogers
Journal: JAMA (1973)

A patient having long-term hemodialysis with uncontrollable thirst, persistent hyponatremia, and expanded extracellular volume was found to have hyperreninemia before and after hemodialysis. The clinical course of this patient and a similar one from the literature confirm previous investigative studies that suggest that elevated levels of circulating renin (angiotensin) may directly stimulate the thirst center of the hypothalamus. Bilateral nephrectomy in both patients resulted in the dramatic cessation of thirst.
Successful open cardiac massage after 75 minutes of closed massage
Authors: E. Shocket
Journal: JAMA (1967)

THIS EXPERIENCE is recorded to refute the belief that 30 to 40 minutes of closed-chest massage is an adequate trial.<sup>1,2</sup>It also refutes the belief that fixed dilated pupils and loss of spontaneous respirations are evidence of irreversible brain damage. <h3>Report of a Case</h3> A 32-year-old white man was treated for ulcerative colitis for 11 years with steroids, sulfonamides, and anticholinergics. Because of multiple, draining perianal fistulae, recurrent rectal hemorrhages, and progressively debilitating fever, a total colectomy was advised. Prior to surgery, the heart, the lungs, and even the abdomen were unremarkable upon examination. A preoperative anemia was corrected by the transfusing of 7 pt of whole blood in six days. An abdominoperineal total colectomy with ileostomy required six hours and 8 pt of blood, but was otherwise uneventful. Four hours after surgery, brisk perineal bleeding dropped the blood pressure to 80/65 mm Hg before a perineal bleeder was
Editor's Choice
Journal: British Journal of Dermatology (2016)

Randomized controlled trial to assess the safety of a novel biological therapy for atopic dermatitisTh e authors of this study from Japan explain that the cytokine interleukin (IL)-31 is considered to be responsible for the development of pruritus in humans.Th ey go on to state that prior to this study, no available evidence has been provided on the safety and effi cacy of blocking the IL-31 signal in humans for the amelioration of pruritus in atopic dermatitis.Th ey studied CIM331, a humanized antihuman IL-31 receptor A (IL-31RA) monoclonal antibody, which binds to IL-31RA to inhibit subsequent IL-31 signalling.Th eir aim was to assess the tolerability, safety, pharmacokinetics and preliminary effi cacy of CIM331 in healthy Japanese and white volunteers, and also in Japanese patients with atopic dermatitis.Th is was a randomized, double-blind, placebo-controlled phase I/Ib study of CIM331, administered in a single subcutaneous dose.Th e primary outcomes were safety and tolerability; the exploratory analysis was effi cacy.Th ere were no deaths, and no serious adverse events (AEs) or discontinuations due to AEs were reported in any part of the study.Additionally, no dosedependent increase in the incidence of AEs occurred in any part of the study.In healthy vol-
AN IMMUNOGENIC PARADOX
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The National Formulary
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Digital Rectal Examination Screening for Prostate Cancer-Reply
Authors: Glenn S. Gerber
Journal: JAMA (1993)

<h3>In Reply.</h3> —We agree with the comments of Drs Maloney and Green. Certainly, the true efficacy of screening requires a demonstration of a reduction in disease-specific mortality. A variety of factors, such as lead-time and length-time biases, as well as possible overdetection of prostate cancer, may falsely suggest benefit from screening when none truly exists. While the National Cancer Institute is undertaking a randomized, prospective trial to study this issue, results will not be available for approximately 16 years. In the meantime, physicians must make their best judgment regarding prostate cancer screening: who should be screened and when and how? In light of recent studies from Europe regarding the excellent 10-year survival of men with well- to moderately differentiated tumors treated by observation and/or palliative therapy alone,<sup>1</sup>it seems reasonable to limit screening to men with at least a 10-year life expectancy. In addition, since the true efficacy of
Ethics
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Journal: Journal for ImmunoTherapy of Cancer (2021)

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to
Abstract 145: Rational Design of a Novel Peptide That Selectively Inhibits δPkc-mediated Pyruvate Dehydrogenase Kinase Phosphorylation Induce Protection From Ischemia and Reperfusion Injury
Authors: Nir Qvit, Daria Mochly-Rosen
Journal: Circulation Research (2017)

Rationale: Protein kinase C delta (δPKC), whose activation induces cardiac injury following heart attack [ischemia andreperfusion (I/R) injury], phosphorylates a number of protein substrates. To determine which of these phosphorylation events is critical to induce cardiac injury, we used a rational approach and identified a novel separation-of-function inhibitor peptide that selectively inhibits specific protein-protein interaction. We showed that following I/R, δPKC-mediated phosphorylation of pyruvate dehydrogenase kinase (PDK) increased PDK-inducedpyruvate dehydrogease phosphorylation, which results in inhibition of ATP regeneration. We therefore determined if selective inhibition of δPKC-mediated PDK phosphorylation alone is sufficient to induce cardiac protection. Methods: We designed a short peptide inhibitor, called ψPDK, to selectively inhibit δPKC binding and phosphorylation of PDK without affecting δPKC-mediated functions. The peptide was used in an ex vivo isolated rat hearts model and in vivo rat model of heart attack [by inducing 30 min ischemia followed by reperfusion (I/R)]. I/R-induced injury was determined by infarct size, cell lysis and activation of stress-induced response. Results: Our approach identified a selective inhibitor of PDK dockingto δPKC with an in vitro Kd of ∼50 nM and reducing cardiac injury IC50 of ∼5 nM. This inhibitor, which did not affect thephosphorylation of other δPKC substrates even at 1 μM, demonstrated that PDK phosphorylation alone is critical for δPKC mediated injury by heart attack.
Parametrically Speaking
Authors: Bruce W. Armstrong
Journal: JAMA (1966)

<h3>To the Editor:—</h3> After a solid ten years of search through dictionaries, indexes, and contexts, your Dr. Schor has finally answered my question, "What the heck is a<i>parameter?</i>" (<b>193</b>:662, 1965). It is a number that describes a population. Well, now! I was a student of Dr. John Kelley's elegant TV program on modern mathematics and am the owner of a copy of his text, unique for its admixture of pathos and science, in which a footnote reads: I'm not quite sure what a parameter is, but I think you call a number a parameter when you're thinking about a function whose domain is a set of numbers. Now if Kelley isn't sure, what he says isn't going to be exactly clear to me, and the situation is pretty grim, when numbers, regardless of what else you call them, start being called parameters. As nearly as I can tell,
A Correction to the Research Article Titled: “Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling” by Y. Yuan, H. Failmezger, O. M. Rueda, H. R. Ali, S. Gräf, S.-F. Chin, R. F. Schwarz, C. Curtis, M. J. Dunning, H. Bardwell, N. Johnson, S. Doyle, G. Turashvili, E. Provenzano, S. Aparicio, C. Caldas, F. Markowetz
Journal: Science Translational Medicine (2012)
Current Comment
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HCV in addiction care: different epidemiology, excellent treatment results
Authors: Ana Arencibia Almeida, Andrea Afonso Díaz, Silvia Acosta-López, Luz Goretti Santiago Gutierrez, Pilar Díaz Ruiz, Magdalena Lara, Antonio González Rodríguez, Javier García Solo de Zaldívar, Francisco Andrés Pérez Hernández, Angel David Febles Gonzalez
Journal: Journal of Hepatology (2020)
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Authors: Michael Kiessling, Alessandra Curioni Fontecedro, Panagiotis Samaras, Michael Scharl, Gehard Rogler
Journal: Journal of Clinical Oncology (2015)

11082 Background: HRAS (Harvey-RAS) is a frequently mutated oncogene in cancer. HRAS is mutated in head and neck cancer (3.9%), bladder cancer (5.1%), vulvar squamous cell carcinoma (9.3%), cutaneous squamous cell carcinoma and lung cancer (3.8%). However, mutant HRAS as a drug target has not been investigated so far. Methods: Cell Proliferation and Viability Assays: Cell proliferation was measured with the Cell-Titer-Glo Reagent (Promega) according to manufacturer's instructions. Cells were plated in clear-bottomed 96-well plates at a density of 500 - 2500 cells per well. The next day, drugs were added at indicatend concentrations and cell proliferation was measured 4 days later. Apoptosis assays:Cell lines were treated with indicated concentrations of inhibitors and apoptosis was measured after 48h and 72h. Apoptosis was assessed by AnnexinV–APC (Enzo Lifescience) and propidium iodide (PI) (Sigma-Aldrich) by FACS. Results: Here, we show that mutant HRAS activates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophagus cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an impact on viability. However, combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Conclusions: Our results show that HRAS mutations in cancer activate the RAS and mTOR pathways which might serve as a therapeutic option for mutated lung cancer patients.
Correction
Journal: BMJ (1955)

age 35 is taken as the lower limit under the heading of Appointments (category VII).On this calculation, out of a total of 430 doctors seeking to establish themselves as principals, or seeking alternative and better openings, 165 (38%) at worst are in blind-alley jobs or at best mark- ing time.This represents 15% of the whole group, and 20% of those who answered the inquiry.
Book Review Why We Get Sick: The New Science of Darwinian Medicine By Randolph M. Nesse and George C. Williams. 291 pp. New York, Times Books, 1995. $24. 0-8129-2224-7 (Published in England as Evolution and Healing: The New Science of Darwinian Medicine). Reinventing Darwin: The great debate at the high table of evolutionary theory By Niles Eldredge. 244 pp. New York, John Wiley, 1995. $27.95. 0-471-30301-1
Authors: Sharon Kingsland
Journal: New England Journal of Medicine (1996)
Exogenous Hematopoietic Stem Cells Can Regenerate Infarcted Myocardium
Authors: D. Orlic, J. Kajstura, S. Chimenti, B. Li, S. Anderson, D. Bodine, J. Pickel, A. Leri, B. Nadal-Ginard, P. Anversa
Journal: Circulation (2000)
Abstract P408: Intake of Fish and Omega-3 Fatty Acids in the United States: Results of an Analysis of NHANES 2007-2010
Authors: Victor L Fulgoni
Journal: Circulation (2013)

The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond recommends ≥ two 3.5-oz fish servings per week (preferably oily fish) partly to increase intake of omega3-fatty acids eicoapentaenoic acid (EPA and docosahexaenoic acid (DHA). We examined the intake of total fish, fish high in omega-3 fatty acids, α-linolenic acid EPA, and DHA in U.S. adults (19+ years) using data from the National Health and Nutrition Examination Survey, 2003-2008. Usual intakes from foods alone and from foods plus dietary supplements were determined using the methods from the National Cancer Institute methods. Mean usual intake of total fish and fish high in omega-3 fatty acids was 0.61 ± 0.03 and 0.15 ± 0.03 oz/day, 0.43 and 0.07 respectively. Total fish and fish high in omega-3 fatty acids median intake was 0.43 and 0.07 oz/day, respectively. Intake from foods alone for ALA, DHA and EPA was 1.5 ± 0.01 g/d, 63 ± 2 mg/d, and 23 ± 7 mg/d, respectively. ALA, DHA and EPA from food only median intakes were 1.4 g/d, 50 mg/d and 18 mg/d, respectively. Intake of ALA, DHA and EPA from foods and dietary supplements was 1.6 ± 0.04 g/d, 72 ± 4 mg/d, and 41 ± 4 mg/d, respectively. While intakes of fish high in omega-3 fatty acids, EPA and DHA were higher in older adults (0.13 ± 0.01 oz/d for those 19-50 yrs and 0.19 ± 0.02 oz/d for those 51+ year; p&lt;0.01) and in males as compared to females (0.18 ± 0.02 vs 0.13 ± 0.01 oz/d, respectively; p&lt;0.05), few are consuming recommended levels. Males also had higher (p&lt;0.05) intake of EPA and DHA from foods and dietary supplements as compared to females (44 ± 6 vs 39 ± 4 and 90 ± 7 vs 59 ± 4 mg/d, respectively) and older adults had higher intakes of EPA but not DHA as younger adults (EPA: 34 ± 3 vs 58 ± 9, P&lt;0.05; DHA: 68 ± 4 vs 81 ± 6, P&gt;0.05). Specific strategies to increase fish high in omega-3 fatty acids need to be developed and if EPA and DHA are important to increase then supplementation may need to be considered.
CHAUVAU'S IMPROVED STETHOSCOPE.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A requiem for the cholecystokinin provocation test?
Authors: S CAMPBELL, R A ELTON, P BRAMLEY;, A SMYTHE, A W MAJEED
Journal: Gut (1999)

Ileal pouch-anal anastomosis forCrohn's disease EDITOR,-In his leading article (Gut 1998;43:303-8), Mr Phillips makes a plea for realistic comparisons between outcomes for pouch surgery in Crohn's disease with other restorative procedures for this disease, rather than comparisons with restorative proctocolectomy for other diseases, specifically ulcerative colitis.We agree that like comparisons are important in scientific analysis, but point out that such comparisons are confounded by the diYculties of accurate histological diagnosis in inflammatory bowel disease.In particular we should like to highlight the diagnostic confusion and unreliability of a change in diagnosis from ulcerative colitis to Crohn's disease based on the histological examination of the defunctioned rectum in ulcerative colitis. 1 Nearly all of the inflammatory changes of Crohn's disease have been described in the defunctioned colorectum in ulcerative colitis. 2 Any change from a diagnosis of ulcerative colitis to Crohn's disease must be based on a reexamination of the colectomy specimen and placed in context with the clinical history.The misdiagnosis of diverted ulcerative colitis, as Crohn's disease, will only add further to the confusion surrounding the debate on the role of the pelvic ileal reservoir in Crohn's disease.
This Week in &lt;emph&gt;JAMA&lt;/emph&gt;
Journal: JAMA (2008)

A Piece of My Mind"Can we decipher how the telling of a story contributes in a meaningful way to the making of a physician?"From "Brew." SEE PAGE 2255 Medical News & PerspectivesStudies and adverse event reports suggest that botulinum toxin may migrate from the site of the injection and have unanticipated adverse effects beyond the injection site.
Not the language of medicine.
Journal: BMJ (1979)

that in his view it is unethical to try to solve this problem by the prison system.1'He urges the NHS to pick up its full responsibility.In summary, there are no easy or well-established remedies ivailable for the mentally disordered offender.The wisest approach may be an empirical one, setting up different schemes an different parts of the country and evaluating their results.
Tumor cells carried through autotransfusion. Contraindication to intraoperative blood recovery?
Authors: P. B. Yaw
Journal: JAMA (1975)

AUTOTRANSFUSION in various forms is a well-recognized and accepted mode of support therapy during major surgical procedures where blood loss is likely or unavoidable. Fecal contamination and spillage of malignant cells have been stated to be contraindications to intraoperative blood recovery, without substantial proof of either contention. Recently, during the care of a patient with carcinoma of the lung, we had occasion to substantiate the transfer of tumor cells from the operative field to blood transfer packs via an autotransfusor. <h3>Report of a Case</h3> A 52-year-old man was admitted to the Marion County General Hospital with a four-week history of hemoptysis, weakness, anorexia, and an 11- to 14-kg (25- to 30-1b) weight loss. He had had a previous episode of hemoptysis about ten years before this admission, a chronic cough, and a 90- to 100-pack/yr smoking habit. The patient appeared cachectic and chronically ill, and was having constant hemoptysis. Blood